Additionally, several studies suggest ICS can suppress the function of the hypothalamic pituitary adrenal axis. [6] [7] [8] [9] [10] While such adverse effects have been detected in research studies, they are thought not to be clinically important. One of us (J.L.F.) has previously reported a significant increase (1.0%) in glycosylated hemoglobin (%GHb) and persistent glucosuria in a patient with type 2 diabetes mellitus and asthma who used inhaled fluticasone propionate (FP) at a high dose (2 mg/day). 11 It is unclear whether lower doses of ICS might disturb glucose metabolism.
In order to assess the effect of anti-asthma therapy on glucose control in patients with type 2 diabetes, we performed a double-blind, double-dummy, randomized, placebo-controlled, crossover investigation analyzing patients treated with inhaled FP, 440 μg twice daily, and the oral leukotriene receptor antagonist, montelukast. The purpose of this investigation was to determine whether moderate doses of inhaled FP (<1 mg/day) adversely affected glucose metabolism in patients with type 2 diabetes.
We compared effects of inhaled FP on glucose metabolism with montelukast, a leukotriene receptor antagonist with no known effects on glucose metabolism, as the control condition.
Leukotriene receptor antagonists are widely used in asthma. They are not indicated in the treatment of COPD, but appear to lead to improved lung function in some patients. 12 
METHODS

Overview
We performed a 12-week randomized, double-blind, double-dummy placebo-controlled, crossover study of inhaled FP (440 μg twice daily) versus oral montelukast (10 mg/day) in non-smoking patients with type 2 diabetes mellitus and stable asthma or COPD (figure 1).
This study was reviewed and approved by the Stanford University Administrative Panel on
Human Subjects in Medical Research and by the Veterans Affairs Palo Alto Health Care
System (VAPAHCS) Research and Development Committee.
Study Participants and Study Setting
Subjects were recruited utilizing advertisements posted on the grounds of the United States Department of VAPAHCS. VAPAHCS operates three hospital-based divisions and six community-based outpatient clinics delivering health care to veterans of the United States military services. All subjects were administered informed consent. Subjects were screened if they were outpatient veterans who reported a physician diagnosis of diabetes that did not require management with insulin and a physician diagnosis of either asthma or COPD.
Participants with type 2 diabetes managed with oral hypoglycemic medication or without medication (diet controlled) were eligible.
Inclusion Criteria
Patients were included if (1) age 18 years or greater, (2) type 2 diabetes confirmed by a fasting plasma glucose >126 mg/dl on a screening visit, and (3) physician diagnosis of either asthma or COPD confirmed by electronic medical record review.
Exclusion Criteria
Patients were excluded if (1) tobacco use within 6 months of enrollment, (2) a history of exacerbation of asthma or COPD within 3 months of enrollment, (3) current insulin use, (4) use of systemic or ICS, leukotriene receptor antagonists, or theophylline within 1 month of enrollment, (5) inability to read and complete a diary card, (6) inability to perform spirometry, peak expiratory flow testing, and (7) inability to use a metered dose inhaler with spacer.
Interventions
After enrollment, participants completed a 3-week run-in period during which they took a placebo inhaler, two puffs twice daily. On day 21 the initial baseline data were obtained including a blood draw for %GHb testing and the randomization was performed in coordination with the research pharmacy at VAPAHCS. A random number generator was used to randomize subjects, in a double-blinded fashion, to receive either inhaled FP (880 μg/day or 2 puffs twice daily of a 220 μg/actuation metered dose inhaler) with a spacer and oral placebo tablets, or inhaled placebo, two puffs twice daily, and oral montelukast (10 mg/day) for 6 weeks. After 6 weeks, subjects crossed over to the opposite treatment limb.
After the second 6-week treatment period, the study was completed (figure 1). At the conclusion of both treatment periods, the research pharmacy disclosed to the investigators the treatment assignment order for each of the study participants. Participants were contacted by telephone once weekly during the study to ensure drug compliance and to assess for adverse events. Subjects were instructed to measure and record their daily peak expiratory flow rate (PEFR) using a hand-held Mini-Wright flow meter (Clement Clarke International, Essex, UK). The study safety limit was specified to be an acute fall in PEFR by more than 20%, or a SMBG measurement >300 mg/dl.
Objectives
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The primary objective was to determine whether inhaled FP at a dose of 440 μg twice daily affects glucose control in patients with type 2 diabetes who have coexistent asthma or COPD.
The primary outcome measure was within-subject difference in %GHb after 6 weeks of fluticasone versus 6 weeks of oral montelukast therapy. The secondary outcome was the within-subject change in %GHb from baseline after each type of therapy.
Outcome Measures
The study was conducted as a crossover design with no washout period between therapies.
%GHb was measured on days 63, at the end of treatment period 1, and on day 105, at the end of treatment period 2, by high performance liquid chromatography (Bio-Rad Variant, BioRad Laboratories, USA). Baseline %GHb for period 1 was the day 21 value; baseline for period 2 was the day 63 value.
Since only six subjects measured SMBG, we used SMBG as a safety rather than an outcome measure in those patients. Weekly mean SMBG was determined by averaging the daily values within each 7-day period. SMBG was measured using the Accu-chek (Roche We anticipated a mean increase of 1.0 in %GHb after fluticasone treatment based on the previous report of one of the authors (J.L.F.). 11 The standard deviation (SD) of %GHb in patients with type 2 diabetes ranges from 0.27 among those with good glucose control and 0.44 among patients with fair control to 1.73 with poor control. 18 Since no previous investigations have studied the effect of ICS on glucose control, we estimated the SD of the change in %GHb from baseline would be 1.0, with no change as a result of oral montelukast therapy. Using these values, we estimated a sample size of 16 patients, using a crossover study design, would be necessary to detect a statistically significant difference between the therapies utilizing a two-tailed t test (α = 0.05, β = 0.20).
Data Collection
Baseline demographic, lung function, and %GHb and fasting blood glucose data were obtained just prior to randomization (table 1) and at 6 and 12 weeks after initiation of therapy. Subjects subsequently recorded daily PEFR in diary cards and subjects performing SMBG recorded results in diary cards. Investigators were blinded to the treatment limb throughout the study.
Statistical Analyses
We included patients with COPD and asthma together in one experimental population. The difference between the mean within-subject changes in %GHb from the relevant baseline to the end of 6 weeks of fluticasone treatment and the mean changes associated with montelukast was evaluated using the paired student's t-test, as were the significance of the changes between baseline and follow-up for each medication. The presence of a carryover effect also was assessed using student's t-test by comparing the observed baseline to 6 week changes in the subjects who received inhaled FP before oral montelukast with those of the 
RESULTS
Fourteen male subjects were recruited, screened, and enrolled in the investigation over a 6 month period. Two subjects were excluded from the study prior to randomization due to noncompliance with the research protocol; 12 were randomized. Two randomized subjects were excluded on day 21 of the first treatment period (one from each study arm) because of noncompliance. Ten subjects completed the investigation, and their baseline characteristics are presented in table 1. Five subjects had a physician diagnosis of asthma and five had COPD.
There was no drop-out for exacerbation of asthma or COPD. There was no study-related adverse event.
The mean within-subject baseline to 6 week difference in %GHb was significantly greater after treatment with inhaled FP than after treatment with oral montelukast therapy (mean within-subject difference = 0.25; P < 0.025) (table 2), but the mean difference was smaller than the 0.5% difference that would be considered clinically relevant and smaller than the 1.0% value the sample size was originally designed to detect. The fact that this difference was statistically significant with only 5 subjects per group is due to the lower-thananticipated variance in the within-subject, within-treatment differences. For 7 subjects %GHb values increased from baseline to 6 weeks on inhaled FP, for 2 subjects they decreased, and for 1 subject they remained the same (figure 2). For 2 subjects %GHb values increased from baseline to 6 weeks on oral montelukast, for 6 subjects they decreased, and for 2 subjects they remained the same (figure 2). Inhaled steroids and glucose control Page 11
After 6 weeks of inhaled FP use, the mean (SD) change in %GHb was +0.11 (0.17), compared with baseline. After 6 weeks of oral montelukast therapy, the mean (± SD) change in %GHb was −0.14 (0.26) (table 2) . During inhaled FP therapy, 7 subjects had an increase in %GHb over their baseline value, 2 had a reduction, and 1 was unchanged. During oral montelukast therapy, 6 subjects had a reduction in GHb, 2 had an increase, and 2 were unchanged relative to their baseline value (figure 2).
Interestingly, of the six subjects who used oral hypoglycemic agents and who measured daily SMBG, four were randomly allocated to receive inhaled FP with oral placebo in period 1 and two were randomly allocated to receive oral montelukast and inhaled placebo in period 1. therapies was significant at week 5 (P < 0.02) and week 6 of therapy (P < 0.05).
Post hoc analysis revealed the presence of a carryover effect (P < 0.02) that resulted in an underestimate of the change in %GHb associated with inhaled FP therapy. There was no significant difference between therapies in terms of weight or serum insulin (table 2) .
DISCUSSION
This is the first (albeit a small) prospective, randomized double-blind, placebo controlled investigation to compare the effects of anti-asthma therapies on glucose metabolism in patients with type 2 diabetes mellitus and co-existing COPD or asthma. We hypothesized that The observed treatment-related changes in %GHb in this study are consistent with our prior report of hyperglycemia and glucosuria in an asthmatic patient with type 2 diabetes mellitus who took very high doses of inhaled FP at a dose of 2 mg/day; however, the mean increase resulting from FP therapy, relative to the individual's own baseline, is substantially smaller than in that individual case. 11 Reduced insulin sensitivity, without hyperglycemia, has been demonstrated in non-diabetic, non-asthmatic adults who took inhaled beclomethasone dipropionate (1 mg per day for 4 weeks) 19 and asthmatic (non-diabetic) children who took inhaled budesonide (0.8 mg/m 2 /day for 4 weeks). 20 In one uncontrolled study, reductions in serum insulin concentrations were observed in non-diabetic patients who took high-dose inhaled steroids for unstable asthma. 21 The authors concluded that this effect was more likely due to a fall in Inhaled steroids and glucose control Page 13 endogenous catecholamines that accompanied the resolution of unstable disease, rather than an effect of inhaled steroid therapy. In another study, 14 normal subjects and 10 nonasthmatic patients with diet-controlled type 2 diabetes mellitus took inhaled placebo for 2 weeks followed by inhaled beclomethasone dipropionate (2 mg/day) for 2 weeks. 22 Inhaled glucocorticoid therapy did not significantly alter glucose tolerance tests and insulin levels after 2 weeks. However, %GHb and SMBG were not measured and the authors comment that an effect might have been observed with prolonged therapy, which also was not explored in the present study. In addition, beclomethasone is less potent than fluticasone as assessed by gene trans-activation and trans-repression. 23 Large intervention studies in patients with type 1 and type 2 diabetes mellitus have demonstrated that intensive glycemic control reduces the onset and delays the progression of microvascular complications, including retinopathy, nephropathy, and neuropathy. 16, [24] [25] [26] [27] [28] Risk reductions in various outcomes ranged between 25% to 75%, and these reductions appeared to be related to the duration and severity of hyperglycemia. 24, 27, 28 The United Kingdom
Prospective Diabetes Study demonstrated a continuous relationship between glycemic control and various complications, such that for a reduction in %GHb of 1.0, there was a 35% reduction in the risk of complications, a 25% reduction in diabetes-related deaths, a 7% decrease in all-cause mortality and an 18% reduction in combined fatal and non-fatal myocardial infarction. 24, 27 Accordingly, modest deterioration in glucose control attributable to anti-asthma therapy, even on the order of the differences observed in this study, could contribute to the development of diabetic complications in at-risk populations. ICS are administered at high dosages. In addition, research is needed to confirm whether small changes in diabetic control are associated with moderate-high dose ICS, on the order of those observed here, and to determine whether these changes are associated with a significant increase in diabetic complications at the population level. 
CONCLUSION
